23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › APELLIS PHARMACEUTICALS INC. › 2023-2024

APELLIS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and APELLIS PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 335Asset managers, any item
  • 1,686Fund votes
  • June 5, 2024Meeting date

Results at a glance

Meeting of June 5, 2024: 4 items on APELLIS PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2024: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 director (22.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore APELLIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by APELLIS PHARMACEUTICALS INC.

These tallies are APELLIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

APELLIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 5, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Paul Fonteyne 98,837,712---- 5,320,2705,506,458 95%Passed (calculated)—
Elect Director: Stephanie Monaghan O'Brien 80,481,023---- 23,672,1525,511,264 77%Passed (calculated)—
The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. 109,564,72756,76242,951 ---- 99.9%Approved—
The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers. 93,573,35710,540,01044,708 --5,506,364 90%Approved—

Source: APELLIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 5, 2024 — read the filing on EDGAR.

How asset managers voted at the APELLIS PHARMACEUTICALS INC. 2023-2024 meeting

335 asset managers disclosed a vote on at least one APELLIS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Paul Fonteyne

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 98,837,712WITHHELD: 5,320,270
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul Fonteyne

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Paul Fonteyne”): 98,837,712 for, 5,320,270 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 43,521,966 for, 48,228 withheld.

FOR
FOR: 43,521,966WITHHOLD: 48,228
Largest asset managers voting on “Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul Fonteyne” at APELLIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard19,541,2310 00For
T. Rowe Price4,453,5930 00For
Fidelity3,465,0860 00For
Prudential/PGIM2,012,2200 00For
Hartford2,008,9790 00For
BlackRock1,530,4740 00For
State Street1,251,2170 01,384For
JPMorgan1,219,4790 00For
Charles Schwab922,3880 00For
Jackson National742,6850 00For
CARILLON SERIES TRUST613,7120 00For
Invesco534,7260 00For
Columbia Threadneedle447,6830 00For
Victory Capital387,7750 00For
Bridge Builder Trust327,8530 00For
Northwestern Mutual282,9990 00For
TIAA265,5770 00For
AIG/SunAmerica263,4620 00For
First Trust244,7690 00For
PIONEER SERIES TRUST II226,8070 00For
Brighthouse210,5880 00For
MUTUAL FUND SERIES TRUST209,7940 00For
Voya196,1050 00For
Aberdeen189,8130 00For
MassMutual184,4480 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Elect Director: Stephanie Monaghan O'Brien

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 80,481,023WITHHELD: 23,672,152
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Monaghan O'Brien

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephanie Monaghan O'Brien”): 80,481,023 for, 23,672,152 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 35,894,361 for, 7,675,833 withheld.

FORWITHHOLD
FOR: 35,894,361WITHHOLD: 7,675,833
Largest asset managers voting on “Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Mona” at APELLIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard19,541,2310 00For
T. Rowe Price4,453,5930 00For
Fidelity3,465,0860 00For
Prudential/PGIM1,951,5370 060,683For
Hartford2,008,9790 00For
BlackRock1,530,4740 00For
State Street13,3340 01,239,267Withhold
JPMorgan1,219,4790 00For
Charles Schwab00 0922,388Withhold
Jackson National448,5370 0294,148Mixed
CARILLON SERIES TRUST00 0613,712Withhold
Invesco00 0534,726Withhold
Columbia Threadneedle00 0447,683Withhold
Victory Capital1,1090 0386,666Withhold
Bridge Builder Trust25,5770 0302,276Mixed
Northwestern Mutual282,9990 00For
TIAA00 0265,577Withhold
AIG/SunAmerica00 0263,462Withhold
First Trust00 0244,769Withhold
PIONEER SERIES TRUST II00 0226,807Withhold
Brighthouse6,7640 0203,824Withhold
MUTUAL FUND SERIES TRUST209,7940 00For
Voya00 0196,105Withhold
Aberdeen00 0189,813Withhold
MassMutual184,4480 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive…

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 93,573,357AGAINST: 10,540,010

Prior year: 93.5% for (June 1, 2023 meeting) ▼ 3.6 pts

Details: description as filed, official tally, votes by 333 asset managers

Description as filed by funds: Approval of an advisory vote on executive compensation; and

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 93,573,357 for, 10,540,010 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(c) The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 91 asset managers voting on “Approval of an advisory vote on executive compensation; and” at APELLIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard19,541,2310 00For
T. Rowe Price4,453,5930 00For
Fidelity3,465,0860 00For
Prudential/PGIM103,4581,908,762 00Mixed
Hartford2,008,9790 00For
BlackRock1,530,4740 00For
State Street1,252,6010 00For
JPMorgan1,219,4790 00For
Charles Schwab922,3880 00For
Jackson National742,6850 00For
CARILLON SERIES TRUST613,7120 00For
Invesco534,7260 00For
Columbia Threadneedle447,6830 00For
Victory Capital387,7750 00For
Bridge Builder Trust327,8530 00For
Northwestern Mutual282,9990 00For
TIAA265,5770 00For
AIG/SunAmerica263,4620 00For
First Trust244,7690 00For
PIONEER SERIES TRUST II226,8070 00For
Brighthouse210,5880 00For
MUTUAL FUND SERIES TRUST209,7940 00For
Voya196,1050 00For
Aberdeen0189,813 00Against
MassMutual184,4480 00For

Fund voting reports, all 91 managers: 41,157,650 for, 2,369,724 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 269 asset managers voting on “Approval of an advisory vote on executive compensation; and” at APELLIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Wellington14,440,7880 00For
EcoR1 Capital, LLC11,607,4250 00For
T. Rowe Price6,912,4290 00For
Avoro Capital Advisors LLC3,764,7830 00For
JENNISON ASSOCIATES LLC03,044,200 00Against
State Street2,629,5160 00For
BlackRock2,398,4280 00For
Fidelity2,287,1116,111 00For
JPMorgan1,930,2570 00For
GEODE CAPITAL MANAGEMENT, LLC1,687,6630 00For
ORBIMED ADVISORS LLC01,297,800 00Against
Octagon Capital Advisors LP1,151,3560 00For
Polar Capital Holdings Plc1,054,4400 00For
Boxer Capital, LLC1,046,8720 00For
Charles Schwab925,2470 00For
Fiera Capital Corp853,9770 00For
EAGLE ASSET MANAGEMENT INC832,3510 00For
PICTET ASSET MANAGEMENT SA820,7060 00For
Logos Global Management LP0800,000 00Against
Victory Capital640,4110 00For
Invesco609,3720 00For
Candriam S.C.A.0589,438 00Against
Iron Triangle Partners LP0475,001 00Against
Citadel465,2670 00For
Northern Trust445,88471 00For

Institutional-manager reports, all 269 managers: 61,224,398 for, 8,685,897 against, 2,237 abstained, 14,297 not voted, 4 unknown. Showing the 25 largest; every one is in the interactive database (link above).

The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 109,564,727AGAINST: 56,762

Prior year: 100.0% for (June 1, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 109,564,727 for, 56,762 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 43,564,895 for, 5,299 against.

FOR
FOR: 43,564,895AGAINST: 5,299
Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm ” at APELLIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard19,541,2310 00For
T. Rowe Price4,453,5930 00For
Fidelity3,465,0860 00For
Prudential/PGIM2,012,2200 00For
Hartford2,008,9790 00For
BlackRock1,530,4740 00For
State Street1,252,6010 00For
JPMorgan1,219,4790 00For
Charles Schwab922,3880 00For
Jackson National742,6850 00For
CARILLON SERIES TRUST613,7120 00For
Invesco534,7260 00For
Columbia Threadneedle447,6830 00For
Victory Capital387,7750 00For
Bridge Builder Trust327,8530 00For
Northwestern Mutual282,9990 00For
TIAA265,5770 00For
AIG/SunAmerica263,4620 00For
First Trust244,7690 00For
PIONEER SERIES TRUST II226,8070 00For
Brighthouse210,5880 00For
MUTUAL FUND SERIES TRUST209,7940 00For
Voya196,1050 00For
Aberdeen189,8130 00For
MassMutual184,4480 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Largest APELLIS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 121,267,000 shares outstanding at the time of that meeting.

Fund voting reports: top APELLIS PHARMACEUTICALS INC. shareholders by shares voted on “Approval of an advisory vote on executive compensation; and”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 16.11%
2T. Rowe Price 3.67%
3Fidelity 2.86%
4Prudential/PGIM 1.66%
5Hartford 1.66%
6BlackRock 1.26%
7State Street 1.03%
8JPMorgan 1.01%
9Charles Schwab 0.76%
10Jackson National 0.61%
Institutional-manager reports: top APELLIS PHARMACEUTICALS INC. shareholders by shares voted on “Approval of an advisory vote on executive compensation; and”, 2023-2024
#Asset manager % of shares outstanding
1Wellington 11.91%
2EcoR1 Capital, LLC 9.57%
3T. Rowe Price 5.70%
4Avoro Capital Advisors LLC 3.10%
5JENNISON ASSOCIATES LLC 2.51%
6State Street 2.17%
7BlackRock 1.98%
8Fidelity 1.89%
9JPMorgan 1.59%
10GEODE CAPITAL MANAGEMENT, LLC 1.39%

Reported APELLIS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

APELLIS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Wellington Management15,058,071 12.42%Form 13F, quarter ended March 31, 2024
Vanguard Group9,987,394 8.24%Form 13F, quarter ended March 31, 2024
Morgan Stanley9,643,248 7.95%Form 13F, quarter ended March 31, 2024
BlackRock6,268,465 5.17%Form 13F, quarter ended March 31, 2024
State Street2,909,528 2.40%Form 13F, quarter ended March 31, 2024
T. Rowe Price2,459,246 2.03%Form 13F, quarter ended March 31, 2024
Geode Capital1,689,890 1.39%Form 13F, quarter ended March 31, 2024
Citadel Advisors1,616,482 1.33%Form 13F, quarter ended March 31, 2024
Norges Bank931,510 0.77%Form 13F, quarter ended March 31, 2024
Charles Schwab924,562 0.76%Form 13F, quarter ended March 31, 2024

Percentages above are of 121,267,000 shares outstanding, as reported by APELLIS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At APELLIS PHARMACEUTICALS INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 335 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,686 separate fund positions. On the most widely held item on that ballot — Approval of an advisory vote on executive compensation; and — APELLIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: APELLIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APELLIS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

APELLIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

Proxy Votes Now, “APELLIS PHARMACEUTICALS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/apellis-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.